Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ultrashort PRS Regimen V for MDR-TB
NCT05278988Phase 4Completed
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Apr 2021
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of bedaquiline, delamanid, clofazimine and pyrazinamide in multidrug-resistant tuberculosis (MDR-TB) (2 arms), sponsored by Shanghai Pulmonary Hospital. Primary endpoint: Patient Cure Rate at 18 months. Started Apr 2021; status: completed.
02
Drugs
bedaquilinedelamanidclofaziminepyrazinamide
03
Conditions
multidrug-resistant tuberculosis (MDR-TB)
Beyond the preview
Go deeper on NCT05278988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05278988.